Compounded Semaglutide: Still Legal in 2026?

Editorial note: This article is a news update covering FDA regulatory action as of May 2026. The regulatory landscape continues to evolve — verify current status with your prescriber and pharmacy before making medication decisions. Linked guides on this site may contain affiliate partnerships; this article itself does not direct readers to affiliate offers.

The short answer is yes — compounded semaglutide remains legal in May 2026 through 503A patient-specific compounding by state-licensed pharmacies. What changed is the broader access pathway: the April 30, 2026 FDA proposed rule excludes semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, foreclosing industrial-scale outsourcing facility compounding. The 503A patient-specific compounding pathway continues to operate under separate statutory authority, though the shortage-status justification that previously simplified compounding workflows is no longer available for semaglutide or tirzepatide.

The longer answer requires understanding what the April 30 notice actually says, what the June 30, 2026 comment deadline means, and the practical difference between the two compounding pathways. The regulatory picture is precise — but it’s been heavily distorted by marketing claims from both compounding telehealth platforms (who position the rules as more permissive than they are) and brand-name manufacturers (who position them as more restrictive). This is the precise May 2026 status without the spin from either side.

What the April 30 Notice Actually Says

On April 30, 2026, the FDA published a Federal Register notice (Docket FDA-2018-N-3240, Federal Register document 2026-08552) proposing to exclude three GLP-1 receptor agonists from the 503B Bulks List — the list of bulk drug substances for which FDA has determined there is a clinical need permitting outsourcing facility compounding from raw active pharmaceutical ingredient.

The three substances proposed for exclusion:

• Semaglutide — the active ingredient in Ozempic, Wegovy, and Rybelsus
• Tirzepatide — the active ingredient in Mounjaro and Zepbound
• Liraglutide — the active ingredient in Victoza and Saxenda

The FDA’s stated rationale: with FDA-approved branded products commercially available, there is no clinical need for 503B outsourcing facilities to compound these medications from bulk substances. The notice explicitly rejects affordability and insurance access as factors that would constitute “clinical need” under the agency’s statutory framework.

Critically, this proposed rule applies specifically to 503B outsourcing facilities. The 503A patient-specific compounding pathway — used by most telehealth platforms operating with state-licensed pharmacy networks — is not directly addressed in this notice. Practical implication: the proposed rule closes one major access pathway (503B industrial-scale compounding) while leaving the other (503A patient-specific compounding) operational under separate regulatory standards.

The public comment period is open through June 30, 2026. After the comment deadline, the FDA will review submissions and issue a final determination. The proposed rule is not yet final — but the agency’s position has been consistent throughout escalating enforcement actions over the past 18 months.

How We Got Here — A 2022-2026 Timeline

Understanding the April 30 notice requires the regulatory backstory. The 503B outsourcing facility framework itself was created by Congress in 2013 in response to the New England Compounding Center (NECC) meningitis disaster, in which contaminated compounded steroid injections caused dozens of deaths and hundreds of fungal meningitis cases across multiple states. The Drug Quality and Security Act of 2013 established 503B as a category of compounders subject to FDA registration and oversight standards closer to traditional pharmaceutical manufacturers — distinct from traditional 503A pharmacies operating under state pharmacy board jurisdiction.

The GLP-1 compounding industry that emerged in 2022-2024 operated within this framework but at scale never anticipated by the 2013 legislation:

• 2022: Semaglutide and tirzepatide added to FDA’s drug shortage list as demand for weight management indications outpaced manufacturer capacity. Section 503A and 503B compounding gains broader legal authority under shortage provisions.
• 2022-2024: Compounded GLP-1 industry expands dramatically. Telehealth platforms (Hims, Ro, LifeMD, Henry Meds, and others) build consumer acquisition funnels serving millions of patients. Becker’s Hospital Review estimated compounded versions reached approximately 30% of total US GLP-1 supply at peak.
• December 19, 2024: FDA resolves the tirzepatide shortage by declaratory order, citing Eli Lilly’s confirmation that manufacturing capacity meets US demand. Tirzepatide has not returned to the shortage list at any point since.
• February 2025: FDA resolves the semaglutide shortage, citing Novo Nordisk capacity expansion. Phased enforcement deadlines established for compounders to wind down operations.
• February 18, 2025: 503A enforcement discretion ends for tirzepatide compounding based on shortage status.
• March 19, 2025: 503B outsourcing facility enforcement discretion ends for tirzepatide.
• April 22, 2025: 503A enforcement discretion ends for semaglutide compounding based on shortage status.
• May 22, 2025: 503B outsourcing facility enforcement discretion ends for semaglutide.
• 2025: Outsourcing Facilities Association (OFA) files federal lawsuits challenging FDA’s shortage resolution determinations. Courts deny preliminary injunctions at the district court level in each case. 5th Circuit appeals remain pending.
• September 2025 onward: FDA escalates enforcement against compounded GLP-1 operations, issuing dozens of warning letters to compounding pharmacies and telehealth platforms throughout the period.
• February 6, 2026: FDA press release “FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs” signals escalating enforcement posture.
• April 30, 2026: Federal Register notice proposes exclusion of semaglutide, tirzepatide, and liraglutide from 503B Bulks List. Comment period opens through June 30, 2026.

The trajectory has been consistent: progressive tightening rather than abrupt prohibition. Each regulatory step narrowed an access pathway without categorically banning compounding.

The “Essentially a Copy” Doctrine

The legal core of FDA’s enforcement posture is the “essentially a copy” doctrine under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The rule: compounding pharmacies cannot lawfully compound drugs that are essentially copies of commercially available FDA-approved products.

How FDA evaluates “essentially a copy”:

• Same route of administration: If the compounded preparation is given by the same route as the commercially available product (e.g., subcutaneous injection), this factor supports an “essentially a copy” finding.
• Same, similar, or substitutable strength: If the active ingredient amounts in the compounded product are within 10% of the strengths of commercially available products, this factor supports “essentially a copy.”
• Combination formulations: A compounded product combining semaglutide with another active ingredient (such as vitamin B12) may still be deemed essentially a copy if the semaglutide and B12 amounts are within 10% of commercially available strengths.

The “4 or fewer prescriptions per month” exemption: The FDA has stated it does not intend to take action against compounders compounding products essentially copying FDA-approved drugs in inordinate amounts, where the compounder fills four or fewer prescriptions per month for that specific compounded product. This narrow exemption preserves limited patient-specific compounding for genuine clinical needs.

Practical implication: 503A pharmacies can compound semaglutide for individual patients with documented clinical justification (allergy to commercial product excipients, non-standard dose, or documented medical necessity for combination formulation), but cannot operate at the industrial scale that characterized 2022-2024 telehealth compounding.

Patient Safety Data Driving the Posture

The FDA’s enforcement posture is anchored in accumulated adverse event data:

• 455+ adverse event reports linked to compounded semaglutide as of early 2025 (current counts higher)
• 320+ adverse event reports linked to compounded tirzepatide as of early 2025 (current counts higher)
• Many reports involve dosing errors from patients self-administering incorrect amounts from multidose vials
• Several reports document hospitalization following severe nausea, dehydration, or pancreatitis
• Concerns about counterfeit products entering supply chains through online channels
• Cold-chain integrity issues with compounded shipments arriving warm or with inadequate temperature controls
• Salt-form substitution risks — products containing semaglutide acetate or sodium rather than semaglutide base used in FDA-approved products

These data points feature prominently in FDA communications and the Federal Register notice rationale. The agency’s framing positions the regulatory tightening as a patient safety response — though critics argue affordability is a competing safety consideration that the framework systematically excludes from “clinical need” evaluation.

“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need. This action reflects our responsibility to protect patients and preserve the integrity of the drug approval process.”

Dr. Marty Makary, FDA Commissioner — April 30, 2026

What This Means for Patients — Drug by Drug

Compounded Semaglutide

• 503A patient-specific compounding: Remains available through licensed 503A pharmacies for individual patients with valid prescriptions. After the February 2025 shortage resolution and April 22, 2025 enforcement deadline, each prescription requires prescriber evaluation and documented clinical rationale — not just shortage status reasoning.
• 503B outsourcing facility compounding: Enforcement discretion ended May 22, 2025. The April 30, 2026 proposed rule would formalize exclusion from the 503B Bulks List.
• Practical reality: Compounded semaglutide continues to be available through compliant telehealth platforms operating with 503A pharmacy networks under valid prescriptions with medical evaluation.

Compounded Tirzepatide

• 503A patient-specific compounding: Legal only through narrow medical necessity exceptions following the February 18, 2025 enforcement deadline. Acceptable rationales include documented polysorbate 80 allergy, non-standard dose or route of administration, or combination formulation with clinical significance beyond convenience.
• 503B outsourcing facility compounding: Effectively foreclosed since the March 19, 2025 enforcement deadline. Tirzepatide was never on the 503B Bulks List, and the April 30 proposed rule would formalize permanent exclusion.
• Shortage status: Resolved December 19, 2024 and has not returned to the FDA shortage list at any point since. Despite some misreporting in industry coverage, tirzepatide has remained off the shortage list throughout 2025-2026.
• Practical reality: Broad telehealth access to compounded tirzepatide has effectively ended. Patients targeting tirzepatide’s higher-dose efficacy now realistically choose between brand-name Zepbound (LillyDirect Self Pay Program at $299-449/month) or transition to compounded semaglutide for moderate weight loss goals.

Compounded Liraglutide

• Shortage status: Liraglutide remains on the FDA shortage list as of May 2026, distinct from semaglutide and tirzepatide.
• Compounding status: Technically still permissible under shortage provisions, though the April 30 proposed rule would foreclose 503B bulk compounding regardless of future shortage status.
• Clinical relevance: Liraglutide has been largely supplanted by weekly GLP-1 alternatives (semaglutide, tirzepatide) due to inferior efficacy and daily injection requirement. Limited clinical demand reduces the practical significance of its continuing compounding availability.

What Compliant Telehealth Providers Are Doing

Telehealth platforms operating in compliance with the May 2026 regulatory framework have adapted their operations in several ways:

• Shift from 503B to 503A pharmacy networks: Platforms that previously relied on 503B outsourcing facilities have transitioned to 503A pharmacy partnerships for ongoing semaglutide compounding.
• Enhanced medical evaluation: Prescriber review and documented clinical rationale have replaced shortage-status reasoning. Telehealth intake forms now collect medical history, contraindications, and clinical justification.
• Tirzepatide deprioritization: Many platforms have either discontinued compounded tirzepatide offerings entirely or restricted them to genuine medical necessity cases. Some have pivoted patients to compounded semaglutide as the primary GLP-1 offering.
• Active ingredient verification: Compliant providers explicitly disclose that they use semaglutide base (not acetate or sodium salt forms) from FDA-registered API manufacturers, and provide Certificate of Analysis documentation for each batch.
• Pharmacy network transparency: Reputable platforms disclose their compounding pharmacy partnerships, allowing verification of 503A licensure on state pharmacy board websites.
• LegitScript certification: Telehealth compliance with industry standards (LegitScript certification) has become a primary differentiator separating compliant operators from quality-risk providers.

For detailed verification criteria and provider evaluation methodology, see: Compounded Semaglutide: The Complete 2026 Guide.

Court Cases Still in Play

The legal challenges to FDA’s enforcement posture continue at the appellate level:

• Outsourcing Facilities Association v. FDA: The OFA filed federal lawsuits challenging the agency’s shortage resolution determinations for both tirzepatide (early 2025) and semaglutide. District courts denied preliminary injunctions in each case — the enforcement deadlines proceeded as scheduled.
• 5th Circuit appeals: The OFA cases are now pending at the Fifth Circuit Court of Appeals. Argument schedules and timing for decision remain uncertain. A successful appeal could theoretically reopen 503B compounding pathways, but the timeline likely extends beyond the June 30 comment deadline.
• Individual pharmacy challenges: Several individual compounding pharmacies have filed challenges to specific warning letters and enforcement actions. These cases proceed on individual records rather than industry-wide rulings.

The judicial posture as of May 2026 has been broadly deferential to FDA’s interpretation of its statutory authority. Whether the 5th Circuit modifies this posture remains the most consequential unresolved question for the compounding industry’s future.

Comment Period and What Happens Next

The Federal Register notice public comment period extends through June 30, 2026. Comments may be submitted via the federal docket at regulations.gov (Docket FDA-2018-N-3240).

Organizations expected to file substantive comments:

• Alliance for Pharmacy Compounding (APC): Industry trade association advocating for 503B compounding authority preservation.
• National Community Pharmacists Association (NCPA): Representing community pharmacy interests, likely favoring broader 503A authority preservation.
• American Society of Health-System Pharmacists (ASHP): Professional society potentially weighing in on clinical need framework.
• Patient advocacy organizations: Some patient groups have voiced concerns about access losses for cost-restricted populations.
• Outsourcing facilities: Individual 503B facilities and their representatives.

After June 30, the FDA will review submissions and issue a final determination. The agency typically takes several months to several years to finalize proposed rules of this complexity. Pending finalization, the April 30 proposal represents FDA’s stated policy position rather than enforceable rule.

The practical impact on May 2026 patient access: minimal change. The proposed rule formalizes a regulatory position that has already been reflected in enforcement actions since early 2025. Compliant 503A compounding through licensed telehealth providers continues operating within the current framework.

Frequently Asked Questions

Is compounded semaglutide illegal now?

No. Compounded semaglutide remains legal under the 503A patient-specific compounding pathway when prepared by licensed compounding pharmacies for individual patients with valid prescriptions, including documented clinical rationale. What ended was the broader shortage-based enforcement discretion that previously allowed industrial-scale compounding by 503B outsourcing facilities and shortage-status reasoning for 503A pharmacies.

What does the April 30 FDA notice mean for my treatment?

If you currently receive compounded semaglutide through a compliant 503A telehealth platform with documented prescriber evaluation, your treatment can continue. The notice primarily affects 503B outsourcing facilities, which most consumer-facing telehealth platforms have already transitioned away from in favor of 503A pharmacy networks. However, the responsibility to verify your provider’s actual compliance posture remains with you — ask explicitly which pharmacy compounds your prescription and whether it operates as 503A or 503B.

Has tirzepatide returned to the FDA shortage list?

No. Tirzepatide was removed from the FDA drug shortage list on December 19, 2024 and has not returned to the shortage list at any point since. Despite some industry coverage incorrectly stating tirzepatide returned to shortage status, the FDA’s published shortage list and Federal Register notices confirm tirzepatide has remained off the shortage list throughout 2025-2026.

When will the FDA finalize the proposed rule?

The comment period closes June 30, 2026. FDA typically takes several months to several years to review comments and finalize complex proposed rules. A final determination by late 2026 or 2027 is plausible but not guaranteed. Until finalized, the proposed rule represents FDA’s stated policy direction rather than enforceable regulation.

Can the courts overturn FDA’s position?

Multiple lawsuits, including the Outsourcing Facilities Association cases, challenge FDA’s shortage resolution determinations and enforcement authority. District courts have ruled in FDA’s favor by denying preliminary injunctions. The 5th Circuit Court of Appeals has the pending appellate cases under review. A successful appellate challenge could theoretically modify FDA’s interpretation, but the litigation timeline likely extends beyond the comment period.

What if my telehealth provider operates with a 503B outsourcing facility?

Most compliant telehealth platforms have transitioned to 503A pharmacy networks for semaglutide compounding. If your current provider operates exclusively with 503B outsourcing facilities for semaglutide, that operation may not be compliant with the May 22, 2025 enforcement deadline. Verify with your provider directly whether their pharmacy network is 503A or 503B, and request documentation of their compliance posture.

Will compounded GLP-1s become unavailable in the US?

Complete unavailability is unlikely in the near term. The 503A patient-specific compounding pathway operates under separate statutory authority than the 503B Bulks List and is not directly affected by the April 30 proposed rule. However, the regulatory direction has clearly tightened over 2024-2026, and additional enforcement actions targeting 503A operations cannot be ruled out. Patients relying on compounded access should remain attentive to provider compliance and have contingency plans for transition to brand-name alternatives if needed.

How many FDA warning letters have been issued?

The FDA has issued dozens of warning letters to compounding pharmacies and telehealth platforms targeting non-compliant compounded GLP-1 operations during 2025-2026. Enforcement activity escalated significantly after September 2025. The pattern indicates active enforcement focus on non-compliant operations rather than blanket prohibition of compounding.

The Bottom Line — May 2026 Status

Compounded semaglutide remains legal in May 2026 through 503A patient-specific compounding when prepared by licensed pharmacies under valid prescriptions with documented clinical rationale. The April 30 proposed rule formalizes the narrowing of access pathways that has been occurring since shortage resolutions in late 2024 and early 2025 — but it does not categorically prohibit compounding.

Compounded tirzepatide has effectively narrowed to genuine medical necessity exceptions only, following the February-March 2025 enforcement deadlines. Telehealth platforms continuing to offer broad compounded tirzepatide access without clinical justification documentation may be operating outside compliant frameworks.

The June 30, 2026 comment deadline matters more for the industry’s medium-term future than for immediate patient access. The Federal Register docket will accept substantive comments from clinicians, patient advocacy organizations, and compounding industry stakeholders. The FDA’s final determination, likely months to years after comment closing, will codify the regulatory framework that governs the next chapter of compounded GLP-1 access in the US.

For patients evaluating current options, the practical question is whether a specific provider operates within the May 2026 compliance framework — 503A pharmacy network, prescriber evaluation with documented clinical rationale, semaglutide base (not salt forms), LegitScript certification, and transparent operating practices. These markers separate compliant operators from quality-risk providers.

For comprehensive analysis of access pathways and provider verification, see our detailed guides:

• Compounded Semaglutide: The Complete 2026 Guide
• Compounded Tirzepatide in 2026: What’s Legal, What’s Not
• Compounded vs Brand GLP-1: The Real 2026 Difference

This article will be updated as the comment period progresses and the FDA issues final determinations. Verify current regulatory status with your prescriber and pharmacy before making medication decisions.